ArticleCureus2026
Severe Transfusion-Dependent Infantile Hemolytic Anemia Associated With a Novel Homozygous PKLR Variant of Uncertain Significance (c.1376C>G, p.Ala459Gly) and Coexisting G6PD Deficiency: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pyruvate kinase deficiency (PKD) results from pathogenic variants in the PKLR gene and demonstrates marked clinical heterogeneity ranging from compensated hemolysis to severe transfusion-dependent anemia; however, novel variants continue to expand the genotypic spectrum of the disease. We report a case of a 10-month-old girl with transfusion-dependent chronic hemolytic anemia found to harbor a novel homozygous PKLR missense variant c.1376C>G (p.Ala459Gly). This variant has not previously been reported in the literature and was classified as a variant of uncertain significance (VUS) according to the American College of Medical Genetics and Genomics/Association for Molecular Pathology (ACMG/AMP) criteria. This report expands the mutational spectrum of PKD and highlights the importance of molecular testing in infants with unexplained chronic hemolytic anemia, especially in populations with high consanguinity rates. Although functional validation of the identified PKLR variant was not available, the patient's clinical and hematologic phenotype was highly consistent with severe PKD, supporting the variant as a candidate disease-associated alteration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.